Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

被引：349

作者：

Ishibashi, Tadashi ^{[1
]}

Horisawa, Tomoko ^{[1
]}

Tokuda, Kumiko ^{[1
]}

Ishiyama, Takeo ^{[1
]}

Ogasa, Masaaki ^{[1
]}

Tagashira, Rie ^{[1
]}

Matsumoto, Kenji ^{[1
]}

Nishikawa, Hiroyuki ^{[1
]}

Ueda, Yoko ^{[1
]}

Toma, Satoko ^{[1
]}

Oki, Hitomi ^{[1
]}

Tanno, Norihiko ^{[1
]}

Saji, Ikutaro ^{[1
]}

Ito, Akira ^{[1
]}

Ohno, Yukihiro ^{[1
]}

Nakamura, Mitsutaka ^{[1
]}

机构：

[1] Dainippon Sumitomo Pharma Co Ltd, Pharmacol Res Labs, Osaka 5640053, Japan

来源：

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2010年 / 334卷 / 01期

关键词：

REVERSES MK-801-INDUCED IMPAIRMENT; GUINEA-PIG; ANTAGONIST SB-269970; DOUBLE-BLIND; WATER MAZE; SCHIZOPHRENIA; RAT; BINDING; MEMORY; SM-9018;

D O I：

10.1124/jpet.110.167346

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned human receptors or membrane fractions prepared from animal tissue. Lurasidone was found to have potent binding affinity for dopamine D-2, 5-hydroxytryptamine 2A (5-HT2A), 5-HT7, 5-HT1A, and noradrenaline alpha(2C) receptors. Affinity for noradrenaline alpha(1), alpha(2A), and 5-HT2C receptors was weak, whereas affinity for histamine H-1 and muscarinic acetylcholine receptors was negligible. In vitro functional assays demonstrated that lurasidone acts as an antagonist at D-2 and 5-HT7 receptors and as a partial

引用

页码：171 / 181

页数：11

共 49 条

[1] ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P615
[2] ARNT J, 1982, ACTA PHARMACOL TOX, V51, P321
[3] The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
Ballard, Michael E.
Basso, Ana M.
Gallagher, Kelly B.
Browman, Kaitlin E.
Fox, Gerard B.
Drescher, Karla U.
Gross, Gerhard
Decker, Michael W.
Rueter, Lynne E.
Zhang, Min
[J]. PSYCHOPHARMACOLOGY, 2007, 190 (01) : 1 - 11
[4] Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
Barnes, TRE
McPhillips, MA
[J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 : S49 - S57
[5] 5-HT2 ANTAGONIST RITANSERIN IN NEUROLEPTIC-INDUCED PARKINSONISM - A DOUBLE-BLIND COMPARISON WITH ORPHENADRINE AND PLACEBO
BERSANI, G
GRISPINI, A
MARINI, S
PASINI, A
VALDUCCI, M
CIANI, N
[J]. CLINICAL NEUROPHARMACOLOGY, 1990, 13 (06) : 500 - 506
[6] Björklund M, 2000, NEUROSCIENCE, V95, P481
[7] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice
Bourin, Michel
Chenu, Franck
Prica, Corina
Hascoet, Martine
[J]. PSYCHOPHARMACOLOGY, 2009, 206 (01) : 97 - 107
[8] CASEY DE, 1996, BR J PSYCHIAT S, V29, P32
[9] HETEROGENEITY OF HISTAMINE H1-RECEPTORS - SPECIES VARIATIONS IN [MEPYRAMINE-H-3 BINDING OF BRAIN MEMBRANES
CHANG, RSL
TRAN, VT
SNYDER, SH
[J]. JOURNAL OF NEUROCHEMISTRY, 1979, 32 (06) : 1653 - 1663
[10] ELLENBROEK BA, 1987, PSYCHOPHARMACOLOGY, V93, P343

← 1 2 3 4 5 →